Outsourcing Labeling Activities in Clinical Trials: Critical Considerations

Outsourcing clinical trial labeling activities is a common practice for sponsors and CROs looking to streamline operations, reduce costs, and tap into specialized capabilities. However, outsourcing does not absolve the sponsor of responsibility. Regulatory authorities like the USFDA and EMA hold sponsors accountable for the quality, compliance, and accuracy of labeling, regardless of who performs the task. This tutorial outlines key risks, responsibilities, and best practices sponsors must monitor when outsourcing labeling for investigational products (IPs).

Why Sponsors Outsource Clinical Labeling:

Labeling in clinical trials is complex and resource-intensive. With global trials, multilingual label requirements, evolving study designs, and interactive response technology (IRT) integration, outsourcing offers several benefits:

• Access to GMP-certified facilities with label printing technology
• Scalability for high-volume or multi-country trials
• Faster turnaround for protocol amendments or changes
• Regulatory familiarity across multiple geographies

However, these advantages come with challenges related to oversight, vendor control, and regulatory compliance, which must be proactively managed.

Risks in Outsourcing Labeling Activities:

• Misprints or incorrect translations
• Uncontrolled label versions or duplication
• Breaches in trial blinding due to labeling errors
• Delayed timelines impacting study drug availability
• Regulatory citations due to insufficient vendor qualification

Many of these issues arise from lack of clarity in sponsor expectations and poorly defined roles. Maintaining compliance starts with robust GMP documentation and agreements.

Key Elements to Monitor When Outsourcing Labeling:

1. Vendor Qualification and Auditing:

Before outsourcing labeling, conduct a formal qualification audit. Assess the vendor’s:

• GMP certification and inspection history
• Label printing technology (digital/thermal/offset)
• Multilingual label capabilities and translation validation
• Computer system validation for label generation (e.g., IRT integration)

Include the vendor in your equipment qualification and supplier management SOPs.

2. Quality Agreement and Scope of Work:

Define responsibilities clearly in a signed quality agreement and scope of work. The agreement must cover:

• Label content approval workflows
• Storage of master label templates
• Control of label materials and print files
• Deviation handling and CAPA reporting
• Change control procedures

3. Label Content Compliance:

Ensure that vendors are familiar with regional labeling requirements, including:

• EU Annex VI / EU CTR labeling rules
• US 21 CFR Part 312.6 label mandates
• Expiration date and storage instructions per expiry dating stability protocols
• Blinding indicators (“For Clinical Trial Use Only,” masked identifiers)

Change Management and Amendments:

In a dynamic clinical trial environment, protocols and dosing regimens change frequently. This requires label updates and reprints. Sponsors must:

• Ensure vendor follows formal change control processes
• Maintain traceability between versions of labels
• Archive obsolete labels to prevent mix-ups
• Reconcile old stock of pre-printed labels

Batch Records and Label Accountability:

Vendors must maintain labeling batch records detailing:

• Label quantities printed and applied
• Lot numbers and batch identifiers
• Signatures of operator and QA reviewer
• Disposition of rejected or unused labels

This documentation must be reviewed by the sponsor’s QA team and filed with the study master file for audit readiness.

Blinding and Randomization Controls:

Labeling vendors must adhere strictly to blinding protocols. Labels linked to treatment arms must be coded and managed securely.

Recommendations:

• Use IRT-integrated label codes with masked kit numbers
• Ensure printing and packing areas are segregated by treatment arm
• Prevent accidental unblinding by controlling label visibility

Incorporate these controls into your pharma SOP documentation for vendor operations and monitoring.

Inspections and Documentation Readiness:

Regulatory agencies may inspect outsourced labeling activities as part of sponsor audits. Sponsors should maintain access to:

• Vendor training records and label control logs
• Environmental monitoring records of labeling rooms
• Change control records and deviation investigations
• QA release records for printed labels

Best Practices for Successful Outsourced Labeling:

1. Define Acceptance Criteria:

• Clearly specify font, format, adhesive, and label placement tolerances
• Pre-approve label proofs before mass production

2. Implement Quality Review Steps:

• Require QA review at vendor site prior to release
• Establish random label sampling for print accuracy

3. Train Internal and Vendor Staff:

• Train sponsor QA and supply chain teams on labeling workflows
• Provide sponsor-approved translation glossaries to vendors

Embed these actions into your pharma regulatory compliance strategy to ensure consistent quality across vendors and countries.

Case Study: Global Phase III Oncology Trial

A sponsor outsourced IP labeling to a GMP-certified vendor across four regions. Quality agreements defined content ownership, audit rights, and deviation management. The vendor used a validated IRT label printer and submitted proof copies for approval. During a protocol amendment, label changes were rapidly implemented, and a change control file maintained for inspection. No labeling deviations occurred throughout the trial.

Conclusion:

Outsourcing labeling activities in clinical trials can enhance operational efficiency, but it requires active oversight, defined quality controls, and robust documentation. Sponsors must audit vendors, formalize agreements, and maintain regulatory visibility throughout the labeling process. With careful planning and compliance integration, outsourced labeling can be a secure, scalable asset for modern clinical trials.